Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$26.97 USD
-0.69 (-2.49%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $26.95 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
MYGN 26.97 -0.69(-2.49%)
Will MYGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MYGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MYGN
Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?
New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues
MYGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term
Alcon's (ALC) Market Share Gains, New Launches Aid Growth
Other News for MYGN
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
Myriad Genetics to Host Investor Event on October 9, 2024
Maintained Buy Rating on Myriad Genetics Amid GeneSight Study Discontinuation
Myriad Genetics study setback unlikely to impact GeneSight, says Leerink
Insider Sale: Director Colleen Reitan Sells Shares of Myriad Genetics Inc (MYGN)